{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:45:37Z","timestamp":1760147137841,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard consolidation strategy for patients with newly diagnosed multiple myeloma (MM) and for a subset of patients with relapsed\/refractory disease. For stem cell mobilization, G-CSF alone or in combination with chemotherapy mobilizing agents and\/or plerixafor are commonly used. Ixazomib is an oral proteasome inhibitor with less neurotoxic potential, which previously showed the ability to mobilize stem cells in preclinical studies. (2) Methods: Prospective single-center phase 1 study assessing the efficacy and safety of stem cell mobilization with ixazomib and G-CSF in patients with newly diagnosed or relapsed\/refractory MM undergoing HDCT and ASCT. Primary endpoint was percentage of patients achieving a yield of at least 6.0 \u00d7 106\/kg CD34+ cells within the first apheresis. G-CSF (filgrastim) 10 \u03bcg\/kg\/day was administered subcutaneously (s.c.) from day 1 to day 5 (planned apheresis) and ixazomib 4 mg orally at day 4. Plerixafor 24 mg s.c. was administered if the stem cell mobilization with ixazomib and G-CSF was not sufficient. (3) Results: 19 patients were treated within the study between 06\/2020 and 02\/2021. The primary endpoint was reached in 17 (89%) patients, with a median of 7.1 \u00d7 106\/kg CD34+ cells collected within the first apheresis, comparable to previously published results, and only 2 (11%) patients required a second apheresis. Median number of circulating CD34+ cells was 14.0 \u00d7 106\/L (2.0\u201395.2) before the administration of ixazomib, and 33.0 \u00d7 106\/L (4.2\u2013177.0) pre-apheresis. However, 9 (47%) patients required the addition of plerixafor to ensure optimal stem cell collection. (4) Conclusions: The combination of ixazomib and G-CSF showed promising stem cell mobilizing activity in patients with MM prior to HDCT and ASCT. Future larger studies might further investigate the role of ixazomib in stem cell mobilization regimens for MM.<\/jats:p>","DOI":"10.3390\/cancers15020430","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T01:57:48Z","timestamp":1673315868000},"page":"430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma"],"prefix":"10.3390","volume":"15","author":[{"given":"Selina","family":"B\u00fchler","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3059","authenticated-orcid":false,"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jeker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-0505","authenticated-orcid":false,"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group","volume":"121","author":"Group","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0043-110224","article-title":"Multiple Myeloma-Current Status in Diagnostic Testing and Therapy","volume":"155","author":"Kehrer","year":"2017","journal-title":"Z. Orthop\u00e4die Unf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current Status of Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"9","author":"Bazarbachi","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_5","first-page":"220","article-title":"Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"62","author":"Ricciuti","year":"2020","journal-title":"Panminerva Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3109\/10428194.2015.1079315","article-title":"Stem Cell Mobilization Chemotherapy with Gemcitabine Is Effective and Safe in Myeloma Patients with Bortezomib-Induced Neurotoxicity","volume":"57","author":"Mueller","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","first-page":"w20031","article-title":"Updated Recommendations for Diagnosis and Treatment of Plasma Cell Myeloma in Switzerland","volume":"149","author":"Samaras","year":"2019","journal-title":"Swiss Med. Wkly."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/10428194.2016.1233542","article-title":"Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Evaluation of Its Safety and Efficacy","volume":"58","author":"Stettler","year":"2017","journal-title":"Leuk. Lymphoma"},{"unstructured":"Straka, C., and Dietzfelbinger, H. (2017). Multiples Myelom, W Zuckschwerdt Verlag. [5th ed.].","key":"ref_9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged Overall Survival with Second On-Demand Autologous Transplant in Multiple Myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.2174\/138161208785061427","article-title":"The Use of Growth Factors in Hematopoietic Stem Cell Transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jca.21591","article-title":"Current Strategies for the Management of Autologous Peripheral Blood Stem Cell Mobilization Failures in Patients with Multiple Myeloma","volume":"33","author":"Sahin","year":"2018","journal-title":"J. Clin. Apher."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","article-title":"Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin\u2019s Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report","volume":"24","author":"Micallef","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/j.clml.2019.04.017","article-title":"A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma","volume":"19","author":"Ghobadi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"doi-asserted-by":"crossref","unstructured":"Forman, S., Negrin, R., Antin, J., and Appelbaum, F. (2016). Thomas\u2019 Hematopoietic Cell Transplantation, Wiley Blackwell. [5th ed.].","key":"ref_17","DOI":"10.1002\/9781118416426"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2021.06.016","article-title":"The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience","volume":"27","author":"Vaxman","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","article-title":"Comparison of the Efficiency, Safety, and Survival Outcomes in Two Stem Cell Mobilization Regimens with Cyclophosphamide plus G-CSF or G-CSF Alone in Multiple Myeloma: A Meta-Analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41409-020-0875-8","article-title":"A Randomized Evaluation of Vinorelbine versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients","volume":"55","author":"Jeker","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","article-title":"Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma","volume":"26","author":"Shah","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"doi-asserted-by":"crossref","unstructured":"Maechler, M., Bacher, U., Daskalakis, M., Nilius, H., Nagler, M., Taleghani, B.M., Jeker, B., and Pabst, T. (Hematol. Oncol., 2022). Long-Term Safety of the Stem Cell Releasing Compound Plerixafor for Peripheral Stem Cell Collection in Myeloma Patients, Hematol. Oncol., Online ahead of print.","key":"ref_22","DOI":"10.1002\/hon.3055"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +\/\u2212 Plerixafor versus Granulocyte Colony-Stimulating Factor +\/\u2212 Plerixafor in the Lenalidomide Era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100771","DOI":"10.1016\/j.blre.2020.100771","article-title":"Getting Blood Out of a Stone: Identification and Management of Patients with Poor Hematopoietic Cell Mobilization","volume":"47","author":"Chen","year":"2021","journal-title":"Blood Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbmt.2017.12.775","article-title":"Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study","volume":"24","author":"Samaras","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbmt.2014.09.020","article-title":"Efficacy of Vinorelbine plus Granulocyte Colony-Stimulation Factor for CD34+ Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma","volume":"21","author":"Samaras","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.leukres.2015.03.015","article-title":"Neurotoxicity of Stem Cell Mobilization Chemotherapy with Vinorelbine in Myeloma Patients after Bortezomib Treatment","volume":"39","author":"Keller","year":"2015","journal-title":"Leuk. Res."},{"doi-asserted-by":"crossref","unstructured":"Mahmoudpour, S.H., Bandapalli, O.R., da Silva Filho, M.I., Campo, C., Hemminki, K., Goldschmidt, H., Merz, M., and F\u00f6rsti, A. (2018). Chemotherapy-Induced Peripheral Neuropathy: Evidence from Genome-Wide Association Studies and Replication within Multiple Myeloma Patients. BMC Cancer, 18.","key":"ref_28","DOI":"10.1186\/s12885-018-4728-4"},{"key":"ref_29","first-page":"193","article-title":"Old and New Generation Proteasome Inhibitors in Multiple Myeloma","volume":"62","author":"Montefusco","year":"2020","journal-title":"Panminerva Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620717710171","article-title":"The Potential of Ixazomib, a Second-Generation Proteasome Inhibitor, in the Treatment of Multiple Myeloma","volume":"8","author":"Brayer","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-10-811620","article-title":"Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Progenitor Cells in Mice","volume":"131","author":"Ghobadi","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1182\/blood-2014-08-595967","article-title":"Bortezomib Is a Rapid Mobilizer of Hematopoietic Stem Cells in Mice via Modulation of the VCAM-1\/VLA-4 Axis","volume":"124","author":"Ghobadi","year":"2014","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exphem.2021.02.009","article-title":"Bortezomib Enhances G-CSF-Induced Hematopoietic Stem Cell Mobilization by Decreasing CXCL12 Levels and Increasing Vascular Permeability","volume":"97","author":"Matsumoto","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_37","first-page":"1157","article-title":"Fluorescent Polymerase Chain Reaction and Capillary Electrophoresis for IgH Rearrangement and Minimal Residual Disease Evaluation in Multiple Myeloma","volume":"87","author":"Novella","year":"2002","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13287-022-02802-6","article-title":"Efficacy of Hematopoietic Stem Cell Mobilization Regimens in Patients with Hematological Malignancies: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Luo","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in Myeloma Revisited: IMWG Consensus Perspectives on Stem Cell Collection Following Initial Therapy with Thalidomide-, Lenalidomide-, or Bortezomib-Containing Regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1703912","article-title":"G-CSF Alone vs Cyclophosphamide plus G-CSF in PBPC Mobilization of Patients with Lymphoma: Results Depend on Degree of Previous Pretreatment","volume":"31","author":"Milone","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/bmt.2011.170","article-title":"Novel Agents and Approaches for Stem Cell Mobilization in Normal Donors and Patients","volume":"47","author":"Bakanay","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","article-title":"Comparison of Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma: High-Dose Cyclophosphamide plus GM-CSF vs G-CSF Alone","volume":"20","author":"Alegre","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14653240701452800","article-title":"Intermediate-Dose CY and G-CSF More Efficiently Mobilize Adequate Numbers of PBSC for Tandem Autologous PBSC Transplantation Compared with Low-Dose CY in Patients with Multiple Myeloma","volume":"9","author":"Hiwase","year":"2007","journal-title":"Cytotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1995.tb05290.x","article-title":"VLA-4 and VCAM-1 Are the Principal Adhesion Molecules Involved in the Interaction between Blast Colony-Forming Cells and Bone Marrow Stromal Cells","volume":"91","author":"Oostendorp","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12185-020-02973-z","article-title":"Bortezomib and Cyclophosphamide Based Chemo-Mobilization in Multiple Myeloma","volume":"112","author":"Bagal","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2015.236","article-title":"A Randomized Phase II Study of Stem Cell Mobilization with Cyclophosphamide+G-CSF or G-CSF Alone after Lenalidomide-Based Induction in Multiple Myeloma","volume":"51","author":"Silvennoinen","year":"2016","journal-title":"Bone Marrow Transplant."},{"unstructured":"Bashir, Q., and Hamadani, M. (2019). Chapter 5-Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection. Hematopoietic Cell Transplantation for Malignant Conditions, Elsevier.","key":"ref_47"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:51Z","timestamp":1760119491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020430"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020430","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}